Abstract:Introduction: Phosphorylation of smooth muscle (SM) myosin regulatory light chain (RLC20) is a critical switch leading to SM contraction. The canonical view held that only the short isoform of myosin light chain kinase (MLCK1) catalyzed this reaction. It is now accepted that auxiliary kinases may contribute to vascular SM tone and contractility. We have previously reported that p90 ribosomal S6 kinase (RSK2) functions as such a kinase, in parallel with MLCK1, contributing ∼25% of the maximal myogenic force in resistance arteries. Thus, RSK2 may be instrumental in the regulation of basal vascular tone and blood pressure. Here, we take advantage of a MLCK1 null mouse (mylk1 -/-) to further test our hypothesis that RSK2 can function as an MLCK, playing a significant physiological role in SM contractility. Methods: Using fetal (E14.5-18.5) SM tissues, as embryos die at birth, we investigated the necessity of MLCK for contractility and fetal development and determined the ability of RSK2 kinase to compensate for the lack of MLCK and characterized its signaling pathway in SM. Results and Discussion: Agonists induced contraction and RLC20 phosphorylation in mylk1 -/- SM was attenuated by RSK2 inhibition. The pCa-tension relationships in permeabilized strips of bladder showed no difference in Ca2+ sensitivity in WT vs mylk1 -/- muscles, although the magnitude of force responses was considerably smaller in the absence of MLCK. The magnitude of contractile responses was similar upon addition of GTPγS to activate the RhoA/ROCK pathway or calyculinA to inhibit the myosin phosphatase. The Ca2+-dependent tyrosine kinase, Pyk2, contributed to RSK2-mediated contractility and RLC20 phosphorylation. Proximity-ligation and immunoprecipitation assays demonstrated an association of RSK2, PDK1 and ERK1/2 with MLCK and actin. RSK2, PDK1, ERK1/2 and MLCK formed a signaling complex on the actin filament, positioning them for interaction with adjacent myosin heads. The Ca2+-dependent component reflected the agonist mediated increases in Ca2+, which activated the Pyk2/PDK1/RSK2 signaling cascade. The Ca2+-independent component was through activation of Erk1/2/PDK1/RSK2 leading to direct phosphorylation of RLC20, to increase contraction. Overall, RSK2 signaling constitutes a new third signaling pathway, in addition to the established Ca2+/CaM/MLCK and RhoA/ROCK pathways to regulate SM contractility.

RSK2 Mediates Muscle Cell Differentiation Through Regulation of NFAT3.

Ribosomal Protein S6 Kinase (RSK)-2 As a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein

SRSF2 is a key player in orchestrating the directional migration and differentiation of MyoD progenitors during skeletal muscle development

LncRNA 4930581F22Rik promotes myogenic differentiation by regulating the ERK/MAPK signaling pathway

LRTM1 promotes the differentiation of myoblast cells by negatively regulating the FGFR1 signaling pathway

Extracellular Signal–Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Pathway is Involved in Myostatin-Regulated Differentiation Repression

Involvement Of Rictor/Mtorc2 In Cardiomyocyte Differentiation Of Mouse Embryonic Stem Cells In Vitro

Mtorc1 and Mtorc2 Play Different Roles in Regulating Cardiomyocyte Differentiation from Embryonic Stem Cells.

p90RSK2, a new MLCK, rescues contractility in myosin light chain kinase null smooth muscle

p90RSK2, a new MLCK mediates contractility in myosin light chain kinase null smooth muscle

CaMKK2 Suppresses Muscle Regeneration Through the Inhibition of Myoblast Proliferation and Differentiation

RSK2 contributes to myogenic vasoconstriction of resistance arteries by activating smooth muscle myosin and the Na+/H+ exchanger

Crucial role of nrf3 in smooth muscle cell differentiation from stem cells.

ERK1/2 Signaling Induces Skeletal Muscle Slow Fiber-Type Switching and Reduces Muscular Dystrophy Disease Severity

Myogenesis controlled by a long non-coding RNA 1700113A16RIK and post-transcriptional regulation

ASAP1 and ARF1 regulate myogenic differentiation in rhabdomyosarcoma by modulating TAZ activity

A Regulatory Mechanism for RSK2 NH(2)-terminal Kinase Activity.

The Association of GSK3β with E2F1 Facilitates Nerve Growth Factor-induced Neural Cell Differentiation

Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase

Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase

RCOR1 promotes myoblast differentiation and muscle regeneration